Literature DB >> 9295169

Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography.

P Hartvig1, R Torstenson, J Tedroff, Y Watanabe, K J Fasth, P Bjurling, B Långström.   

Abstract

Positron emission tomography (PET) was used in a multitracer protocol to evaluate D-amphetamine induced effects on dopamine biosynthesis rate and release in propofol anesthetized Rhesus monkeys. L-[beta-11C]DOPA was used as biochemical probe to study the brain dopamine biosynthesis rate whilst dopamine release was followed by the binding displacement of the [11C]-radiolabelled dopamine receptor antagonists, raclopride and N-methylspiperone. Studies were performed with either a constant rate intravenous infusion of D-amphetamine aiming at plasma concentrations of 0.2 to 25 ng/ml or with intravenous bolus doses of 0.1 and 0.4 mg/kg. Decreased binding of the dopamine receptor antagonists was measured in both modes of D-amphetamine administration but notably [11C]N-methylspiperone was less able to sense D-amphetamine induced release of dopamine. At plasma concentrations aimed above 1 ng/ml a levelling off of the binding of [11C]raclopride at 68 +/- 8.1% of the baseline value indicated that displacement was only possible from a fraction of the binding sites. Amphetamine was observed to increase the rate constant for L-[beta-11C]DOPA utilization in the brain. This was most likely due to an acutely induced subsensitivity of presynaptic dopamine receptors. L-[beta-11C]DOPA and [11C]raclopride were found suitable to indicate changes in dopamine synthesis rate and release respectively using PET and can be used to mirror drug-induced changes of brain dopaminergic function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9295169     DOI: 10.1007/BF01277655

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  29 in total

1.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.

Authors:  D J Brooks; V Ibanez; G V Sawle; E D Playford; N Quinn; C J Mathias; A J Lees; C D Marsden; R Bannister; R S Frackowiak
Journal:  Ann Neurol       Date:  1992-02       Impact factor: 10.422

2.  Molecular mechanisms of cocaine addiction.

Authors:  A I Leshner
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

3.  Simultaneous correction for tracer arrival delay and dispersion in CBF measurements by the H215O autoradiographic method and dynamic PET.

Authors:  E Meyer
Journal:  J Nucl Med       Date:  1989-06       Impact factor: 10.057

4.  Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels.

Authors:  S L Dewey; G S Smith; J Logan; J D Brodie; J S Fowler; A P Wolf
Journal:  Synapse       Date:  1993-04       Impact factor: 2.562

5.  Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis.

Authors:  P Herscovitch; J Markham; M E Raichle
Journal:  J Nucl Med       Date:  1983-09       Impact factor: 10.057

6.  Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis.

Authors:  R Kuczenski; D Segal
Journal:  J Neurosci       Date:  1989-06       Impact factor: 6.167

7.  Long-term amphetamine treatment attenuates or reverses the depression of neuronal activity produced by dopamine agonists in the ventral tegmental area.

Authors:  K Kamata; G V Rebec
Journal:  Life Sci       Date:  1984-06-11       Impact factor: 5.037

8.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter.

Authors:  B Giros; M Jaber; S R Jones; R M Wightman; M G Caron
Journal:  Nature       Date:  1996-02-15       Impact factor: 49.962

9.  Brain kinetics of L-[beta-11C]dopa in humans studied by positron emission tomography.

Authors:  P Hartvig; H Agren; L Reibring; J Tedroff; P Bjurling; T Kihlberg; B Långström
Journal:  J Neural Transm Gen Sect       Date:  1991

10.  Synthesis of L- and D-[methyl-11C]methionine.

Authors:  B Långström; G Antoni; P Gullberg; C Halldin; P Malmborg; K Någren; A Rimland; H Svärd
Journal:  J Nucl Med       Date:  1987-06       Impact factor: 10.057

View more
  15 in total

Review 1.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

2.  Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans.

Authors:  Paul Shotbolt; Andri C Tziortzi; Graham E Searle; Alessandro Colasanti; Jasper van der Aart; Sergio Abanades; Christophe Plisson; Sam R Miller; Mickael Huiban; John D Beaver; Roger N Gunn; Marc Laruelle; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2011-08-31       Impact factor: 6.200

Review 3.  Imaging the dopamine system with in vivo [11C]raclopride displacement studies: understanding the true mechanism.

Authors:  Nathalie Ginovart
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

4.  Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette.

Authors:  Arthur L Brody; Mark A Mandelkern; Richard E Olmstead; Zoe Allen-Martinez; David Scheibal; Anna L Abrams; Matthew R Costello; Judah Farahi; Sanjaya Saxena; John Monterosso; Edythe D London
Journal:  Neuropsychopharmacology       Date:  2008-06-18       Impact factor: 7.853

5.  Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers.

Authors:  Ningning Guo; Wen Guo; Michaela Kralikova; Man Jiang; Ira Schieren; Raj Narendran; Mark Slifstein; Anissa Abi-Dargham; Marc Laruelle; Jonathan A Javitch; Stephen Rayport
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

6.  Blood levels and DA transporter occupancy of orally administered methylphenidate in juvenile rhesus monkeys measured by high resolution PET.

Authors:  Kristin M Wilcox; Yun Zhou; Dean F Wong; Mohab Alexander; Arman Rahmim; John Hilton; Michael R Weed
Journal:  Synapse       Date:  2008-12       Impact factor: 2.562

7.  Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride.

Authors:  Jens C Pruessner; Frances Champagne; Michael J Meaney; Alain Dagher
Journal:  J Neurosci       Date:  2004-03-17       Impact factor: 6.167

8.  The nature of dopamine dysfunction in schizophrenia and what this means for treatment.

Authors:  Oliver D Howes; Joseph Kambeitz; Euitae Kim; Daniel Stahl; Mark Slifstein; Anissa Abi-Dargham; Shitij Kapur
Journal:  Arch Gen Psychiatry       Date:  2012-08

9.  The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study.

Authors:  Michael A P Bloomfield; Celia J A Morgan; Shitij Kapur; H Valerie Curran; Oliver D Howes
Journal:  Psychopharmacology (Berl)       Date:  2014-04-03       Impact factor: 4.530

10.  No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT.

Authors:  Gerda Thomsen; Gitte Moos Knudsen; Peter S Jensen; Morten Ziebell; Klaus K Holst; Susanne Asenbaum; Jan Booij; Jacques Darcourt; John C Dickson; Ozlem L Kapucu; Flavio Nobili; Osama Sabri; Terez Sera; Klaus Tatsch; Livia Tossici-Bolt; Koen Van Laere; Thierry Vander Borght; Andrea Varrone; Marco Pagani; Lars Hageman Pinborg
Journal:  EJNMMI Res       Date:  2013-05-20       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.